AM-1241
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524172

CAS#: 444912-48-5

Description: AM-1241 is a chemical from the aminoalkylindole family that acts as a potent and selective agonist for the cannabinoid receptor CB2. It has analgesic effects in animal studies, particularly against "atypical" pain such as hyperalgesia and allodynia.


Chemical Structure

img
AM-1241
CAS# 444912-48-5

Theoretical Analysis

MedKoo Cat#: 524172
Name: AM-1241
CAS#: 444912-48-5
Chemical Formula: C22H22IN3O3
Exact Mass: 503.0705
Molecular Weight: 503.33
Elemental Analysis: C, 52.50; H, 4.41; I, 25.21; N, 8.35; O, 9.54

Price and Availability

Size Price Availability Quantity
1.0mg USD 205.0 2 Weeks
5.0mg USD 355.0 2 Weeks
10.0mg USD 565.0 2 Weeks
Bulk inquiry

Synonym: AM-1241; AM 1241; AM1241; UNII-DLM851L3RD.

IUPAC/Chemical Name: (1-(Methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole)

InChi Key: ZUHIXXCLLBMBDW-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3

SMILES Code: CN1CCCCC1Cn2cc(c3c2cccc3)C(=O)c4cc(ccc4I)[N+](=O)[O-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 503.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yu SJ, Reiner D, Shen H, Wu KJ, Liu QR, Wang Y. Time-Dependent Protection of CB2 Receptor Agonist in Stroke. PLoS One. 2015 Jul 17;10(7):e0132487. doi: 10.1371/journal.pone.0132487. eCollection 2015. PubMed PMID: 26186541; PubMed Central PMCID: PMC4505877.

2: Bujalska-Zadrożny M, de Cordé A, Pawlik K. Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. Pharmacol Rep. 2015 Apr;67(2):209-16. doi: 10.1016/j.pharep.2014.08.023. Epub 2014 Sep 16. PubMed PMID: 25712641.

3: Ma L, Jia J, Liu X, Bai F, Wang Q, Xiong L. Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling. Biochem Biophys Res Commun. 2015 Feb 27;458(1):92-7. doi: 10.1016/j.bbrc.2015.01.073. Epub 2015 Jan 27. PubMed PMID: 25637536.

4: Janero DR, Makriyannis A. Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems. ACS Chem Neurosci. 2014 Nov 19;5(11):1097-106. doi: 10.1021/cn5000875. Epub 2014 Jun 5. Review. PubMed PMID: 24866555.

5: Greco R, Mangione AS, Sandrini G, Nappi G, Tassorelli C. Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain. 2014 Mar 17;15:14. doi: 10.1186/1129-2377-15-14. PubMed PMID: 24636539; PubMed Central PMCID: PMC3995520.

6: Wang Y, Ma S, Wang Q, Hu W, Wang D, Li X, Su T, Qin X, Zhang X, Ma K, Chen J, Xiong L, Cao F. Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart. Sci China Life Sci. 2014 Feb;57(2):201-8. doi: 10.1007/s11427-013-4604-z. Epub 2014 Jan 15. PubMed PMID: 24430557.

7: Avraham HK, Jiang S, Fu Y, Rockenstein E, Makriyannis A, Zvonok A, Masliah E, Avraham S. The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol. 2014 Jan;171(2):468-79. doi: 10.1111/bph.12478. PubMed PMID: 24148086; PubMed Central PMCID: PMC3904265.

8: Cui JH, Ju J, Yoon MH. Pharmacology of cannabinoid receptor agonists and a cyclooxygenase-2 inhibitor in rat bone tumor pain. Pharmacology. 2013;92(3-4):150-7. doi: 10.1159/000354296. Epub 2013 Sep 4. PubMed PMID: 24008428.

9: Marini P, Cascio MG, King A, Pertwee RG, Ross RA. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol. 2013 Jun;169(4):887-99. doi: 10.1111/bph.12191. PubMed PMID: 23711022; PubMed Central PMCID: PMC3687668.

10: Ribeiro R, Wen J, Li S, Zhang Y. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat. 2013 Jan;100-101:1-14. doi: 10.1016/j.prostaglandins.2012.11.003. Epub 2012 Dec 5. PubMed PMID: 23219970.

11: Paronis CA, Thakur GA, Bajaj S, Nikas SP, Vemuri VK, Makriyannis A, Bergman J. Diuretic effects of cannabinoids. J Pharmacol Exp Ther. 2013 Jan;344(1):8-14. doi: 10.1124/jpet.112.199331. Epub 2012 Sep 27. PubMed PMID: 23019138; PubMed Central PMCID: PMC3533417.

12: Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res. 2013 Jan;28(1):92-107. doi: 10.1002/jbmr.1732. PubMed PMID: 22903605; PubMed Central PMCID: PMC4745976.

13: Wood JT, Smith DM, Janero DR, Zvonok AM, Makriyannis A. Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci. 2013 Mar 19;92(8-9):482-91. doi: 10.1016/j.lfs.2012.06.019. Epub 2012 Jun 28. PubMed PMID: 22749867; PubMed Central PMCID: PMC3493696.

14: Su TF, Zhao YQ, Zhang LH, Peng M, Wu CH, Pei L, Tian B, Zhang J, Shi J, Pan HL, Li M. Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB2 receptors. Eur J Pain. 2012 May;16(5):624-35. doi: 10.1002/j.1532-2149.2011.00055.x. Epub 2011 Dec 19. PubMed PMID: 22337285.

15: Gamaleddin I, Zvonok A, Makriyannis A, Goldberg SR, Le Foll B. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One. 2012;7(1):e29900. doi: 10.1371/journal.pone.0029900. Epub 2012 Jan 26. PubMed PMID: 22291896; PubMed Central PMCID: PMC3266883.

16: Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV. Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. J Neuroimmunol. 2012 Mar;244(1-2):23-31. doi: 10.1016/j.jneuroim.2011.12.021. Epub 2012 Jan 30. PubMed PMID: 22285397; PubMed Central PMCID: PMC3298577.

17: Jiang S, Fu Y, Avraham HK. Regulation of hematopoietic stem cell trafficking and mobilization by the endocannabinoid system. Transfusion. 2011 Nov;51 Suppl 4:65S-71S. doi: 10.1111/j.1537-2995.2011.03368.x. PubMed PMID: 22074629.

18: Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, Salvidio G, Di Marzo V, Cavallo Perin P, Gruden G. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes. 2011 Sep;60(9):2386-96. doi: 10.2337/db10-1809. Epub 2011 Aug 1. PubMed PMID: 21810593; PubMed Central PMCID: PMC3161308.

19: Curto-Reyes V, Boto T, Hidalgo A, Menéndez L, Baamonde A. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice. Eur J Pharmacol. 2011 Oct 1;668(1-2):184-9. doi: 10.1016/j.ejphar.2011.06.057. Epub 2011 Jul 13. PubMed PMID: 21771590.

20: Khasabova IA, Gielissen J, Chandiramani A, Harding-Rose C, Odeh DA, Simone DA, Seybold VS. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol. 2011 Sep;22(5-6):607-16. doi: 10.1097/FBP.0b013e3283474a6d. PubMed PMID: 21610490; PubMed Central PMCID: PMC3155626.

AM-1241

1.0mg / USD 205.0